United States Renin-Inhibitors Market with CAGR of 6.7% during 2024-2031 - Exclusive Report by DatamIntelligence

"Renin-Inhibitors Market is expected to grow at a CAGR of 6.7% during the forecast period (2024-2031)." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/renin-inhibitors-market?sp

United States: Recent Industry Developments

✅ In July 2025, AstraZeneca announced plans to seek regulatory approval for its experimental blood pressure drug baxdrostat by the end of the year. The drug targets aldosterone, a hormone that regulates blood pressure, and has shown promising results in clinical trials. If approved, baxdrostat could offer a novel approach to hypertension treatment.

✅ In June 2025, Alnylam Pharmaceuticals reported positive results from the KARDIA-2 study for zilebesiran, an investigational small interfering RNA (siRNA) therapeutic. The therapy significantly reduces serum angiotensinogen levels and blood pressure in patients with hypertension, offering a comprehensive blockade of the renin-angiotensin-aldosterone system.

✅ In May 2025, Novartis announced a $50 million investment to expand research on its pipeline of next-generation renin inhibitors, focusing on precision therapies for resistant hypertension and high-risk cardiovascular patients.

✅ In March 2025, Bayer Pharmaceuticals initiated a multi-center clinical trial for its novel renin inhibitor BAY 1214784, aiming to evaluate safety and efficacy in patients with chronic kidney disease and hypertension.

Japan: Recent Industry Developments

✅ In October 2025, Daiichi Sankyo launched clinical studies for its new renin inhibitor candidate targeting severe hypertension. The initiative received ¥1 billion in government and private sector funding to accelerate research and development.

✅ In August 2025, Takeda Pharmaceuticals partnered with a Japanese biotech startup to develop an AI-driven platform for designing renin inhibitors, securing ¥800 million in joint investments to enhance drug discovery efficiency.

✅ In June 2025, Astellas Pharma received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to conduct phase II trials of its oral renin inhibitor ASP-1788 in hypertensive patients with renal complications.

✅ In April 2025, Chugai Pharmaceutical announced a ¥500 million investment to advance its research on renin inhibitors aimed at reducing cardiovascular risk in high-risk hypertensive patients.

Renin-Inhibitors Market: Drivers

The renin-inhibitors market is witnessing steady growth, driven by increasing prevalence of hypertension, cardiovascular disorders, and chronic kidney disease, which necessitate effective renin-angiotensin-aldosterone system (RAAS) modulation. Renin inhibitors, by directly targeting renin, help regulate blood pressure, reduce vascular resistance, and manage heart and kidney-related complications, offering an alternative or complement to ACE inhibitors and angiotensin receptor blockers. Advances in drug formulation, sustained-release delivery systems, and combination therapies are enhancing efficacy, patient compliance, and safety profiles. Expansion of healthcare infrastructure, screening programs for hypertension, and growing awareness of cardiovascular health are further supporting market adoption. Rising focus on preventive cardiology, early intervention, and personalized treatment approaches is boosting demand for renin inhibitors globally.

Leading pharmaceutical companies, including Novartis, Takeda, and Almirall, are developing innovative renin-inhibiting therapies with improved pharmacokinetics, potency, and tolerability. Research into dual RAAS inhibitors, combination therapies, and novel molecular targets is expanding therapeutic options and patient outcomes. Strategic collaborations between pharma companies, healthcare providers, and research institutions are accelerating clinical trials, regulatory approvals, and commercialization. Increasing awareness among healthcare professionals and patients about hypertension management and cardiovascular risk reduction is driving adoption. With continuous drug innovation, rising prevalence of hypertension and cardiovascular diseases, and growing emphasis on effective chronic disease management, the renin-inhibitors market is poised for sustained global growth.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/renin-inhibitors-market?sp

Renin-Inhibitors Market: Major Players

Novartis, Noden Pharma DAC, and others.

Segment Covered in the Renin-Inhibitors Market:

➥ By Drug: TEKTURNA (aliskiren), TEKTURNA HCT (aliskiren/hydrochlorothiazide)

➥ By Product Type: 150mg/Tablet, 300mg/Tablet, Other

Research Process:

Both primary and secondary data sources have been used in the Renin-Inhibitors Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Most Frequently Asked Questions in the Renin-Inhibitors Market Research Industry:

➠ Who leads the Renin-Inhibitors industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Renin-Inhibitors market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Renin-Inhibitors market growth?
➠ What are the dominant sales and distribution strategies in the Renin-Inhibitors industry?

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=renin-inhibitors-market

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.